A Phase 2 interventional study of 400 µg Brimonidine Tartrate Implant and 200 µg Brimonidine Tartrate Implant in Macular Degeneration, sponsored by Allergan. Completed at 7 sites in 7 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-08-21.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Macular Degeneration by AbbVie — 3 open to participants now, 6 under way, 3 of them phase 3. Macular Degeneration · AbbVie.
Among the 22 studies in Macular Degeneration by AbbVie, this one is the 12th largest by enrollment, is one of 2 that started in 2008, is one of 12 in phase 2, and was the 4th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 22 studies in Macular Degeneration by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Austria, Belgium and 14 more countries
Ages 50+
AbbVie · Sites in United States
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 15 · Phase 3 5
First in 2004; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 122 across the 22 interventional studies. Of the 16 that completed or were terminated, 13 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
1 of the studies in Macular Degeneration by AbbVie that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Macular Degeneration by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Stage 1 is a patient-masked, dose-escalation, safety evaluation of brimonidine intravitreal implant. Patients will receive implant in one eye and "sham" treatment (meaning no treatment) in the fellow eye. Stage 2 will begin after 1 month of safety has been evaluated for Stage 1. Stage 2 is a randomized, double-masked, dose-response, sham-controlled evaluation of the safety and efficacy of brimonidine intravitreal implant in patients with geographic atrophy from age-related macular degeneration. Patients will be followed for up to 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Stage 1: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
Drug: 400 µg Brimonidine Tartrate Implant · Other: Sham (no implant)
Stage 1: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
Drug: 200 µg Brimonidine Tartrate Implant · Other: Sham (no implant)
Stage 2: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
Drug: 400 µg Brimonidine Tartrate Implant · Other: Sham (no implant)
Stage 2: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
Drug: 200 µg Brimonidine Tartrate Implant · Other: Sham (no implant)
Stage 2: sham in both eyes on Day 1 and Month 6.
Other: Sham (no implant)
400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
Also known as: Brimonidine Tartrate PS DDS®
200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
Also known as: Brimonidine Tartrate PS DDS®
Sham in one or both eyes on Day 1 and Month 6.
Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye
Change from baseline in size of geographic atrophy lesion area in the study eye is based on fundus photography as read by an independent Reading Center. Photographs are taken with a specialized microscope with an attached camera to photograph the interior of the eye, including the retina and optic disc. A positive change from baseline indicates an increase in size of geographic atrophy lesion area (worsening; disease progression). Data are reported in disc area where 1 disc area = 1.767 millimeters squared (mm\^2).
Time frame: Baseline, Month 12
Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye
Change from baseline in size of geographic atrophy lesion area in the study eye is based on fundus photography as read by an independent Reading Center. Photographs are taken with a specialized microscope with an attached camera to photograph the interior of the eye, including the retina and optic disc. A positive change from baseline indicates an increase in size of geographic atrophy lesion area (worsening; disease progression). Data are reported in disc area where 1 disc area = 1.767 millimeters squared (mm\^2).
Time frame: Baseline, Month 3, Month 6, Month 9, Month 18, Month 24
Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.
Time frame: Baseline, 24 Months
Change From Baseline in Contrast Sensitivity in the Study Eye
Change from baseline in contrast sensitivity in the study eye is measured using a Pelli-Robson contrast sensitivity chart at 1 meter. The contrast sensitivity chart contains letters that are darkest at the top and then get progressively lighter. Scores range from 0 to 48 and are based on the number of letters read correctly. A negative change from baseline indicates a worsening in contrast sensitivity and a positive change from baseline indicates an improvement.
Time frame: Baseline, 24 Months
Change From Baseline in Reading Speed in the Study Eye
Change from baseline in reading speed in the study eye is assessed using modified Bailey-Lovie word charts. Patients read the chart for 2 minutes and the numbers of words read correctly per minute are totaled. An increase in the number of words read correctly indicates an improvement and a decrease in the number of words read correctly indicates a worsening.
Time frame: Baseline, 24 Months
| Milestone | 400 µg Brimonidine Tartrate Implant Stage 1 | 200 µg Brimonidine Tartrate Implant Stage 1 | 400 µg Brimonidine Tartrate Implant Stage 2 | 200 µg Brimonidine Tartrate Implant Stage 2 | Sham (no Implant) Stage 2 |
|---|---|---|---|---|---|
| Started | 3 | 3 | 41 | 49 | 23 |
| Completed | 3 | 2 | 31 | 37 | 21 |
| Not completed | 0 | 1 | 10 | 12 | 2 |
Change from baseline in size of geographic atrophy lesion area in the study eye is based on fundus photography as read by an independent Reading Center. Photographs are taken with a specialized microscope with an attached camera to photograph the interior of the eye, including the retina and optic disc. A positive change from baseline indicates an increase in size of geographic atrophy lesion area (worsening; disease progression). Data are reported in disc area where 1 disc area = 1.767 millimeters squared (mm\^2).
| Disc Area | 400 µg Brimonidine Tartrate Implant Stage 2 | 200 µg Brimonidine Tartrate Implant Stage 2 | Sham (no Implant) Stage 2 |
|---|---|---|---|
| Baseline | 6.219 ± 3.9524 | 6.897 ± 4.6397 | 5.526 ± 4.7890 |
| Change from Baseline at Month 12 | 0.898 ± 0.7520 | 1.006 ± 0.7858 | 1.239 ± 1.1645 |
Change from baseline in size of geographic atrophy lesion area in the study eye is based on fundus photography as read by an independent Reading Center. Photographs are taken with a specialized microscope with an attached camera to photograph the interior of the eye, including the retina and optic disc. A positive change from baseline indicates an increase in size of geographic atrophy lesion area (worsening; disease progression). Data are reported in disc area where 1 disc area = 1.767 millimeters squared (mm\^2).
| Disc Area | 400 µg Brimonidine Tartrate Implant Stage 2 | 200 µg Brimonidine Tartrate Implant Stage 2 | Sham (no Implant) Stage 2 |
|---|---|---|---|
| Baseline | 6.219 ± 3.9524 | 6.897 ± 4.6397 | 5.526 ± 4.7890 |
| Change from Baseline at Month 3 | 0.182 ± 0.3353 | 0.117 ± 0.6612 | 0.399 ± 0.3713 |
| Change from Baseline at Month 6 | 0.482 ± 0.6325 | 0.570 ± 0.5749 | 0.609 ± 0.5474 |
| Change from Baseline at Month 9 | 0.641 ± 0.6847 | 0.798 ± 0.6424 | 0.857 ± 0.7267 |
| Change from Baseline at Month 18 | 1.306 ± 1.0164 | 1.413 ± 1.0291 | 1.697 ± 1.4185 |
| Change from Baseline at Month 24 | 1.744 ± 1.4010 | 1.991 ± 1.4469 | 2.178 ± 1.7042 |
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.
| Number of Letters Read Correctly | 400 µg Brimonidine Tartrate Implant Stage 2 | 200 µg Brimonidine Tartrate Implant Stage 2 | Sham (no Implant) Stage 2 |
|---|---|---|---|
| Baseline | 54.8 ± 12.89 | 52.1 ± 13.91 | 53.7 ± 10.71 |
| Change from Baseline at 24 Months | -5.0 ± 13.77 | -3.2 ± 12.87 | -3.3 ± 12.98 |
Change from baseline in contrast sensitivity in the study eye is measured using a Pelli-Robson contrast sensitivity chart at 1 meter. The contrast sensitivity chart contains letters that are darkest at the top and then get progressively lighter. Scores range from 0 to 48 and are based on the number of letters read correctly. A negative change from baseline indicates a worsening in contrast sensitivity and a positive change from baseline indicates an improvement.
| Number of Letters Read Correctly | 400 µg Brimonidine Tartrate Implant Stage 2 | 200 µg Brimonidine Tartrate Implant Stage 2 | Sham (no Implant) Stage 2 |
|---|---|---|---|
| Baseline | 23.7 ± 5.60 | 22.1 ± 5.76 | 21.7 ± 7.56 |
| Change from Baseline at 24 Months | -0.9 ± 4.33 | 1.1 ± 7.22 | 0.6 ± 7.49 |
Change from baseline in reading speed in the study eye is assessed using modified Bailey-Lovie word charts. Patients read the chart for 2 minutes and the numbers of words read correctly per minute are totaled. An increase in the number of words read correctly indicates an improvement and a decrease in the number of words read correctly indicates a worsening.
| Words per Minute (wpm) | 400 µg Brimonidine Tartrate Implant Stage 2 | 200 µg Brimonidine Tartrate Implant Stage 2 | Sham (no Implant) Stage 2 |
|---|---|---|---|
| Baseline | 10.21 ± 8.532 | 9.62 ± 9.224 | 8.72 ± 6.832 |
| Change from Baseline at 24 Months | -1.15 ± 5.527 | -0.28 ± 7.035 | 0.45 ± 4.705 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 400 µg Brimonidine Tartrate Implant | — | 14/43 (32.6%) | 38/43 (88.4%) |
| 200 µg Brimonidine Tartrate Implant | — | 20/51 (39.2%) | 47/51 (92.2%) |
| Sham (no Implant) Stage 2 | — | 9/23 (39.1%) | 20/23 (87%) |
| Event | 400 µg Brimonidine Tartrate Implant | 200 µg Brimonidine Tartrate Implant | Sham (no Implant) Stage 2 |
|---|---|---|---|
| Spinal Compression FractureInjury, poisoning and procedural complications | 0/43 | 0/51 | 2/23 |
| AnaemiaBlood and lymphatic system disorders | 0/43 | 1/51 | 1/23 |
| Acute Myocardial InfarctionCardiac disorders | 1/43 | 1/51 | 1/23 |
| Atrial FibrillationCardiac disorders | 1/43 | 1/51 | 1/23 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 0/43 | 0/51 | 1/23 |
| PneumoniaInfections and infestations | 1/43 | 1/51 | 1/23 |
| Clostridium Difficile ColitisInfections and infestations | 0/43 | 0/51 | 1/23 |
| DiverticulitisInfections and infestations | 0/43 | 0/51 | 1/23 |
| Urinary Tract Infection BacterialInfections and infestations | 0/43 | 0/51 | 1/23 |
| Hip FractureInjury, poisoning and procedural complications | 1/43 | 1/51 | 1/23 |
| Event | 400 µg Brimonidine Tartrate Implant | 200 µg Brimonidine Tartrate Implant | Sham (no Implant) Stage 2 |
|---|---|---|---|
| Conjunctival HaemorrhageEye disorders | 12/43 | 21/51 | 2/23 |
| HypertensionVascular disorders | 2/43 | 1/51 | 4/23 |
| Conjunctival HyperaemiaEye disorders | 3/43 | 7/51 | 3/23 |
| AnaemiaBlood and lymphatic system disorders | 1/43 | 5/51 | 3/23 |
| NauseaGastrointestinal disorders | 0/43 | 3/51 | 3/23 |
| Back PainMusculoskeletal and connective tissue disorders | 1/43 | 0/51 | 3/23 |
| Punctate KeratitisEye disorders | 5/43 | 1/51 | 0/23 |
| Eye PainEye disorders | 5/43 | 1/51 | 1/23 |
| Urinary Tract InfectionInfections and infestations | 3/43 | 5/51 | 2/23 |
| CataractEye disorders | 4/43 | 3/51 | 1/23 |
| Age, Continuous(Years) | 400 µg Brimonidine Tartrate Implant Stage 1 | 200 µg Brimonidine Tartrate Implant Stage 1 | 400 µg Brimonidine Tartrate Implant Stage 2 | 200 µg Brimonidine Tartrate Implant Stage 2 | Sham (no Implant) Stage 2 | Total |
|---|---|---|---|---|---|---|
| Mean | 85.0 ± 3.61 | 79.0 ± 3.00 | 75.6 ± 8.78 | 77.0 ± 9.13 | 78.4 ± 5.80 | 77.0 ± 8.33 |
| Sex: Female, Male(Participants) | 400 µg Brimonidine Tartrate Implant Stage 1 | 200 µg Brimonidine Tartrate Implant Stage 1 | 400 µg Brimonidine Tartrate Implant Stage 2 | 200 µg Brimonidine Tartrate Implant Stage 2 | Sham (no Implant) Stage 2 | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 2 | 27 | 28 | 12 | 72 |
| Male | 0 | 1 | 14 | 21 | 11 | 47 |
Ran from May 2008 to primary completion in Jun 2010, 25 months.
Results were first posted in Apr 2013, 2 years 10 months after primary completion. A results delay was requested in Jun 2011.
Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 25 months is above that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine